What's Hot
View all perspectives
Dr. John Cush RheumNow
1 year 4 months ago
Promising new therapies in SLE
Dr. Yuz Yusof ( @Yuz6Yusof ) weighs in.
The pharmacology treatment in SLE is a rapidly expanding field of research that provides excitement and optimism to both the patients and the clinicians.
https://t.co/0G6EMYp2mb https://t.co/Yc31sR4fRE
Dr. John Cush RheumNow
1 year 4 months ago
An update on JAK inhibitors and cardiovascular risks
Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors.
https://t.co/yZqHEg73bn https://t.co/CzVH62LEgL
Dr. John Cush RheumNow
1 year 4 months ago
RheumNow Eular 2023 Daily Recap Series https://t.co/oZXuyv8wL5
David Liew drdavidliew
1 year 4 months ago
The key data for treating clinically suspect arthralgias (CSA):
TREAT-EARLIER (MTX)
ARIAA, APIPPRA (abatacept)
but what we need to do going forward:
stratify pts better for studies
predict individual risk better, to weight up risk-benefit of intervention
#EULAR2023 @RheumNow https://t.co/h3gNIyLxPY
David Liew drdavidliew
1 year 4 months ago
Key arguments for CSA skeptics:
- definitions, imaging aren’t anywhere near as good as our own suspicion as clinicians is
- we still struggle to prevent RA
- it’s easy to go down a therapeutic slippery slope, and hard to track back
- labels are hard to remove
#EULAR2023 @RheumNow https://t.co/4adop3IR8g
Dr. Antoni Chan synovialjoints
1 year 4 months ago
Presenting work to improve referrals from primary care, reducing delays in diagnosis in rheumatic conditions. Sharing the set up of Rheumatology Academy and Collaborative Network (RheumACaN) and the impact it is making @RBNHSFT @NASSexercise @RheumatologyUK @RheumNow #EULAR2023 https://t.co/v0BBRiFtEy
Dr. John Cush RheumNow
1 year 4 months ago
Check out RheumNow's #EULAR23 coverage!
https://t.co/rGBWF0lx4g https://t.co/6SEon6poi4
Dr. John Cush RheumNow
1 year 4 months ago
RheumNow’s expanded coverage of the #EULAR2023 annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow
1 year 4 months ago
RheumNow Eular 2023 Daily Recap Series https://t.co/ScW9jWvzl9
David Liew drdavidliew
1 year 4 months ago
So Annette van der Helm-van Mil makes some clear arguments about why CSA is real. But Filip Van den Bosch gives his disclosure: the clinical rheumatologist’s inherent skepticism of ‘early disease’
#EULAR2023 @RheumNow https://t.co/GbaBhQE5AB
Dr. John Cush RheumNow
1 year 4 months ago
ILD in RA and PsA
@AurelieRheumo discusses inconsistent data inconsistent data have proposed on the effect of bio/tsDMARDs on the risk of ILD.
ILD is a severe extra articular manifestation of RA, with limited treatment strategies and poor prognosis.
https://t.co/U1RjvgTCL8 https://t.co/qmxXBTK05N
Poster Hall